Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networksJiajun Xu(University of Glasgow), Reza Akhavan‐Sigari(University of Tübingen)Cell CycleFebruary 16, 202410.1080/15384101.2024.2340859Cited by 3SaveCiteExport RISWatch citationsRelated PapersProgressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation|Molecular Cancer|2023|956